Highlights

  • Argent BioPharma signed an exclusive licence agreement covering Tollovir, Tollovid and NutraVir products.
  • The licence applies worldwide excluding China.
  • The agreement includes upfront payments, milestone payments and Royalty arrangements.
  • Performance rights associated with the agreement remain subject to Shareholder approval.
  • Commercial outcomes depend on future sales, regulatory developments and product activities.

Argent BioPharma Limited (ASX:RGT) is a biotechnology company focused on developing and commercialising healthcare products. The company’s latest announcement outlines an exclusive licence agreement with NLC Ltd. and Dr Dorit Arad covering Tollovir, Tollovid and NutraVir, including intellectual property rights, payment arrangements and future commercial milestones.

Licence Agreement Overview

Argent BioPharma announced that it has entered into an exclusive worldwide licence agreement, excluding China, with NLC Ltd. and Dr Dorit Arad for Tollovir, Tollovid and NutraVir products. The company stated that existing TolloHealth rights in the United States for Tollovid remain preserved under the arrangement.

The licensed products cover different applications. Tollovir relates to antiviral applications outlined in the agreement, while Tollovid is licensed for antiviral applications. NutraVir is described as a dietary supplement and is not claimed to diagnose or treat disease.

Intellectual Property Rights

The licence includes intellectual property associated with the products, including United States Patent 11,857,517 titled 'Compounds for Treating Coronavirus Infection', related applications and an international patent application covering botanical antiviral composition technology.

The agreement also includes trademark-related rights associated with Tollovid, NLC-V, Todos Medical and NutraVir. Argent stated that the licence provides access to these intellectual property Assets within the agreed territory.

Financial Terms and Royalties

Under the agreement, Argent will make monthly payments of US$15,000 for 20 months from execution. The company will also contribute US$30,000 towards legal expenses and purchase NutraVir inventory under the terms outlined in the agreement.

The agreement includes sales milestone payments of US$100,000 when cumulative net sales reach US$2.5 million and US$125,000 when cumulative net sales reach US$5 million.

Royalty payments are structured on a tiered basis, with rates applied separately for each product. The royalty structure includes different rates depending on cumulative sales levels achieved.

Performance Rights and Approvals

The consideration package also includes 2,000,000 performance rights. The company stated that these rights are subject to shareholder approval and will vest based on achievement of specified sales milestones.

The proposed performance rights issue requires shareholder approval under the applicable listing rules. Argent has scheduled a shareholder meeting for November 2026 to consider the proposed issue.

Commercial Considerations

The licence agreement provides Argent with rights to commercialise the covered products, although the company has noted that commercial value depends on achieving future sales milestones and market development objectives.

The announcement does not provide information on current product sales, regulatory approvals or clinical outcomes associated with the licensed products. Future updates will depend on product development, commercial activities and regulatory processes.

Key Insights

Argent BioPharma’s latest announcement outlines a licensing arrangement that expands access to antiviral-related products and associated intellectual property. The agreement provides a framework for commercialisation activities, while future value creation depends on sales performance, approvals and execution of the agreed milestones.